Skip to Main Content
Home Books Pharmacotherapy: A Pathophysiologic Approach, 10e

Section 14: Hematologic Disorders

  • Sections
  • Print
  • Get Citation

    Citation

    Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy.

    AMA Citation
    Hematologic Disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. DiPiro J.T., & Talbert R.L., & Yee G.C., & Matzke G.R., & Wells B.G., & Posey L(Eds.),Eds. Joseph T. DiPiro, et al.eds. Pharmacotherapy: A Pathophysiologic Approach, 10e. McGraw-Hill; Accessed July 12, 2020. https://accesspharmacy.mhmedical.com/content.aspx?bookid=1971&sectionid=147388954
    APA Citation
    Hematologic disorders. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. DiPiro J.T., & Talbert R.L., & Yee G.C., & Matzke G.R., & Wells B.G., & Posey L(Eds.),Eds. Joseph T. DiPiro, et al. (2016). Pharmacotherapy: A Pathophysiologic Approach, 10e. McGraw-Hill. https://accesspharmacy.mhmedical.com/content.aspx?bookid=1971&sectionid=147388954
    MLA Citation
    "Hematologic Disorders." Pharmacotherapy: A Pathophysiologic Approach, 10e DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. DiPiro J.T., & Talbert R.L., & Yee G.C., & Matzke G.R., & Wells B.G., & Posey L(Eds.),Eds. Joseph T. DiPiro, et al. McGraw-Hill, 2016, https://accesspharmacy.mhmedical.com/content.aspx?bookid=1971&sectionid=147388954.

    Download citation file:

    RIS (Zotero)
    EndNote
    BibTex
    Medlars
    ProCite
    RefWorks
    Reference Manager
    Mendeley
    © Copyright
  • Tools
  • Search Book
  • Clip
Top

Section 14: Hematologic Disorders

The genetic inheritance pattern for hemophilia is:

A. Autosomal dominant

B. Autosomal recessive

C. X-linked

D. Genetic polymorphism

The answer is C.

The factor deficit in hemophilia B is:

A. Factor II

B. Factor VII

C. Factor VIII

D. Factor IX

The answer is D.

Which of the following is not considered a goal of Hemophilia therapy?

A. Prevent bleeding episodes

B. Prevent long term complications

C. Eradicate inhibitors

D. Arrest bleeding if it occurs

The answer is C.

Patients with severe hemophilia have ______% factor activity level.

A. <1%

B. 1-4%

C. 3-5%

D. >5%

The answer is A.

The first-line therapeutic approach to treating an active bleed in a patient with severe hemophilia without inhibitors is:

A. Plasma derived factor replacement

B. Recombinant factor replacement

C. Activated prothrombin complex concentrates (aPCCs)

D. Desmopressin

E. Anti-thrombolytic

The answer is B.

Which is a true statement regarding prophylaxis therapy for hemophilia?

A. Not recommended by any national organization

B. Recommended approach but optimal dosing and schedule is not well defined

C. Proven cost effective

D. Patient compliance is not a factor in overall outcome

The answer is B.

The most impactful therapeutic complication of therapy for hemophilia patients is:

A. Infection

B. Cost

C. Inhibitor formation

...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MHE Privacy Center Close